secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-08-27T23:59:59+00:00
Accession:  0001104659-25-083402
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics' BXCL501 meets primary endpoint in SERENITY At-Home Phase 3 trial for agitation
--------------------------------------------------------------------------------

- Phase 3 SERENITY At-Home trial met primary safety endpoint; no drug-related SAEs, syncope, or falls in 2,437 episodes treated with 120 mcg BXCL501.
- No discontinuations due to tolerability in BXCL501 arm; adverse event profile consistent with approved IGALMI label.
- Company plans sNDA submission for label expansion to at-home setting in Q1 2026; market opportunity estimated at 57–77 million annual episodes in US.
- Exploratory efficacy data show greater percentage of patients achieved full agitation resolution with BXCL501 vs placebo, with consistent benefit across repeat dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925083402/0001104659-25-083402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925083402/tm2524474d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-083402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer